Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection.
Ramos-Casals
M
M
Department of Autoimmune Diseases, Clinical Institutes of Infection and Immunology, Insitut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Department of Medicine, School of Medicine, University of Barcelona, Spain. mramos@clinic.ub.es
Trejo
O
O
García-Carrasco
M
M
Font
J
J
D000998:Antiviral Agents / Q000627:therapeutic use*; D018771:Arthralgia / Q000188:drug therapy; D001168:Arthritis / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000821:virology*; D005938:Glucocorticoids / Q000627:therapeutic use; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy; D017285:Polymyositis / Q000188:drug therapy; D011658:Pulmonary Fibrosis / Q000188:drug therapy; D012859:Sjogren's Syndrome / Q000188:drug therapy; D013966:Thyroiditis / Q000188:drug therapy; D014657:Vasculitis / Q000188:drug therapy
D000998:Antiviral Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016898:Interferon-alpha